Therefore, our aim was to quantify tissue CPs in vivo during CKD evolution in a mouse model of subtotal (75%) surgical kidney reduction to demonstrate CP accumulation in tissues during CKD and thus provide new arguments in favour of the involvement of carbamylation in CKD complications. The gene discussed is CP; the disease is chronic kidney disease.